Fertility has become a routine topic in general practice with 88% of GPs reporting discussing fertility-related issues with patients on a regular basis.

But while the conversations are frequent, many clinicians report a lack of clarity when it comes to referral pathways, treatment options, and clinic relationships.

If you’re running a pharmaceutical marketing campaign in Australia, AHPRA verification isn’t optional — it’s essential. This article explains why marketing to an unverified audience wastes budget, creates compliance risk, and why a verified HCP audience is the foundation of every effective campaign.

The adoption of digital health technologies is growing, but many doctors remain hesitant due to concerns about security, usability, and workflow disruption. To accelerate adoption, digital health tech companies must focus on practical solutions that address these challenges.

The digital transformation of healthcare is well underway, with doctors increasingly turning to technology to improve efficiency and patient care. However, while adoption is growing, familiarity and confidence in digital health solutions remain mixed, highlighting the need for better integration and support.

Artificial Intelligence (AI) is increasingly being integrated into healthcare, promising to enhance efficiency, reduce administrative burdens, and improve patient outcomes. Yet why do so many doctors remain sceptical about its adoption.

Open-ended responses from a recent AusDoc survey provide valuable qualitative insights into how prescribing practices for GPs and specialists can be improved. These responses highlight key themes and practical recommendations for enhancing access to information and support for healthcare professionals.

Understanding the unique needs of GPs and specialists is pivotal for fostering better prescribing practices. By tailoring resources and engagement strategies, stakeholders can support informed decisions, ultimately improving patient care outcomes.

An AusDoc survey has highlighted an opportunity for the pharmaceutical industry to help speed up the pathway to diagnosis and treatment of patients with rare diseases.

While eight in every hundred Australians has a rare disease, GPs lack confidence in identifying these patients, which may delay diagnosis and treatment.